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Abstract:  
A new simple, accurate, precise and reproducible RP-HPLC method has been developed for the 
simultaneous estimation of Aspirin and Omeprazole in bulk and pharmaceutical dosage form 
using C18 column (Agilent, 250 x 4.6 mm, 5 μm) in isocratic mode. The mobile phase consisted 
of  Methanol & 0.1 M Dipotassium Phosphate buffer (pH 3)  in the ratio of 60:40 v/v. The 
detection was carried out at 256 nm . The method was linear over the concentration range for 
Omeprazole 50-250 μg/ml and for Aspirin 10-50 μg/ml. The recoveries of Omeprazole and 
Aspirin were found to be 100.07 and 100.06% respectively. The validation of method was 
carried out utilizing ICH-guidelines. The described HPLC method was successfully employed 
for the analysis of pharmaceutical formulations containing combined dosage form. 
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Introduction:  
Aspirin (ASP) is chemically 2-(acetyloxy)-benzoic acid (Figure 1). It is nonselective 
cyclooxygenase inhibitor used as an antipyretic, analgesic, anti-inflammatory, and 
antithrombotic agent. Esomeprazole magnesium (ESO) is S-isomer of omeprazole and proton 
pump inhibitor. It is magnesium, bis [5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-
pyridinyl)methyl]sulfinyl]-1H-benzimidazolato] (Figure 2). It is used in treatment of peptic ulcer 
disease, NSAIDS-associated ulceration and Zollinger-Ellison syndrome, used as antiulcerative. 
ASP and ESO in combined dosage form are used in cardiovascular disorder and cerebrovascular 
disorders [1–3] 
                                 Figure 1: Structure of aspirin. 
 Figure 2: Structure of esomeprazole . 
The review of literature revealed that various analytical methods involving spectrophotometry 
[5-7], HPLC [8-11] and HPTLC [12] have been reported for ASP in single form and in 
combination with other drugs. Several analytical methods have been reported for ESO in single 
form and in combination with other drugs including spectrophotometry [13, 14], HPLC [15, 16], 
and HPTLC [17]. 
The present work describes the development of a simple, precise, accurate, and reproducible 
HPLC method for the simultaneous estimation of ASP and ESO in combined dosage form. The 
 developed method was validated in accordance with ICH Guidelines [1&18] and successfully 
employed for the assay of ASP and ESO combine dosage form. 
Materials 
ASP and OMP were received gratis from Hetero drugs, Hyderabad and were used as received. 
HPLC grade Methanol was purchased from SD Fine Chem Pvt. Ltd. (Mumbai, Maharashtra). 
Ultra-pure water was obtained from ELGA (Bucks, UK) water purification unit. Waters total 
recovery vials (Waters, Milford, MA, USA) were of glass type 1, class A with 950 μL maximal 
injectable volumes. All other chemicals were of analytical reagent grade. 
EXPERIMENTAL WORK: 
Chromatographic conditions 
The HPLC system (LC Waters, Milford, MA, USA) consisted of quaternary gradient system 
(600 Controller), in-line degasser (Waters, model AF), photodiode array detector (Water, 2998 
model) and auto sampler (Waters, model 717 plus). Data was processed using Empower Pro 
software (Waters, Milford, MA, USA).  
Isocratic elution of the mobile phase 0.1 M Dipotassium Phosphate buffer (pH 3) and Methanol 
in the ratio of 40:60 v/v with the flowrate of 1 ml/min. Separation was performed on a Waters 
C18 (250 x 4.6 mm i.d, 5 μ particle size) analytical column and a pre-column to protect the 
analytical column from strongly bonded material. Integration of the detector output was 
performed using the Waters Empower software to determine the peak area. The contents of the 
mobile phase were filtered through a 0.45 µm membrane filter and degassed by sonication before 
use. Mobile phase was used as diluents. 
The flow rate of the mobile phase was optimized to 1 ml/min which yields a column back 
pressure of 110–112 kg/cm. The run time was set at 6 min and a column temperature was 
maintained at 35°C. The volume of injection was 10 µl, prior to injection of the analyte, the 
column was equilibrated for 30–40 min with the mobile phase. The eluents were detected at 256 
nm. The developed method was validated in terms of specificiy, linearity, accuracy, limit of 
detection (LOD), limit of quantification(LOQ), intra-day and inter-day precision and robustness 
for the assay of ASP and OMP as per ICH guidelines. 
Preparation of standard solutions 
ASP and OMP were weighed (10 mg each) and transferred to two separate 10 ml volumetric 
flasks and dissolved in 5 ml of water and make up the volume up to the mark with mobile phase. 
Working standards of the drugs were prepared from this solution. 
Preparation of sample solution: 
Twenty tablets (Yosprala, Make:Aralez Pharmaceuticals) were weighed. Anaccurately weighed 
amount of the finelypowdered tablets equivalent to 10mg was made up to 10mL with mobile 
phase. The solution was filtered followed by serial dilution to the required concentrations for 
each experiment. 
Results and Discussion:  
Method Development: 
Number of mobile phase and their different proportions were tried and finally was selected as 0.1 
M Dipotassium Phosphate buffer (pH 3) and Methanol in the ratio of 40:60 v/v appropriate 
mobile phase which gave good resolution and acceptable system suitability parameters. The 
results of system suitability parameters were shown in table 2. The chromatogram of working 
standard solution is shown in Fig 3. The summary of Chromatographic conditions was given in 
table 1. 
 
 
 Table 1: Summary of Chromatographic conditions 
S. No Parameter Description/Value 
1. Stationary Phase Water’s C18 (250X4.6X5)  
2 Mobile Phase 
0.1 M Dipotassium Phosphate buffer (pH 
3) and Methanol in the ratio of 40:60 v/v 
3 Flow rate 1 ml/min 
4 Detection Wavelength 256 nm 
5 Detector Photo diode array 
6 Injection auto sampler -Waters, model 717 plus 
7 Rt’s 
Omeprazole – 2.323Min 
Aspirin     –     4..342 Min 
8 Injection volume 10 μl 
9 Column Temperature 35 °C 
10 Run time 6 mins 
11 Diluent Mobile Phase 
 
 
Fig.3 Typical Chromatogram of  Omeprazole & Aspirin 
 
Table 2: System suitability parameters 
 
S. No Parameter Result 
Omeprazole Aspirin 
1 Retention Time 2.323 min     4.325  min 
2 Tailing 1.079 1.189 
3 Theoretical Plates  (n) 5076 7837 
4 Resolution factor (R) 3.08 
5 Similarity Factor 1.0124 (Limit: 0.98 – 1.2) 
 
Method Validation: 
Accuracy 
Recovery assessment was obtained by using standard addition technique which was by adding 
known quantitiesof pure standards at three different levels in 50%, 100%and 150% to the pre 
analysed sample formulation. From the amount of drug found, amount of drug recoveredand 
percentage recovery were calculated which sense to conformation that the proposed method was 
accurate. The results were tabulated in Table 3. 
 
 
 
 Table 3: Results of Accuracy 
S. 
No 
% 
Concentration 
(at specific 
level) 
Omeprazole Aspirin 
Amount 
added (µg) 
Amount 
found (µg) 
Mean % 
Recovery 
Amount 
added (µg) 
Amount 
found (µg) 
Mean % 
Recovery 
1 50 75 75 100* 15 15 100* 
2 100 150 149.25    99.13**         30 30 100** 
3 150 225 224.89     99.69* 45 44.55 99* 
*Mean % Recovery of 6 replicates; **Mean % Recovery of 3 replicates 
Precision 
The intraday and interday precision of the proposed methodwas determined by analyzing mixed 
standard solution of OMP and ASP at concentration 150 µg/mL and 30 µg/mL, 3 times on the 
same day and on 3 different days. The results shown in table 4 were reported in terms of relative 
standard deviation. 
 
Table 4: Results of Precision (%Assay) 
 
 
 
 
 
 
 
 
 
 
Linearity 
Calibration graphs were constructed by plotting peak area vs concentration of ASP and OMP and 
the regression equations were calculated. The calibration graphs were plotted over 5different 
linear concentrations in the range of 10-50µg/ml for ASP and 50-250 µg/ml for OMP. Aliquots 
(10 µl) of each solution were injected under the operating chromatographic condition described 
above [Number of replicates (n =6)]. The linearity graphs were shown in fig 4 & 5. 
       
                                              
 
Fig 4: Linearity of Omeprazole 
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Sample No. Omeprazole Aspirin 
Sample Area - 1 %  Assay - 1 Sample Area - 2 %  Assay - 2 
1 2194758 100.06 1456296 100 
2 2195700 99.49 1457422 100 
3 2196191 99.14 1456513 98 
4 2195326 100.27 1454579 99 
5 2200951 100.27 1451483 99 
6 2196585 100.39 1455259 99 
Average Assay: 100 Average Assay: 99 
STD 0.51 STD 0.82 
%  RSD 0.51 % RSD 0.83 
  
Fig 4: Linearity of Aspirin 
Limit of detection (LOD) and limit of quantitation(LOQ): 
The limit of detection (LOD) and limit of quantitation (LOQ) of ASP and OMP were determined 
by calculating the signal-to-noise(S/N) ratio of 3:1 and 10:1, respectively according to 
International Conference on Harmonization guidelines.LOD values for ASP and OMP were 
found to be 3.08and 3.041 µg/mL respectively. LOQ values for C were found to be 10.37 and 
9.79µg/mL respectively. 
Assay of the tablet dosage form 
The proposed validated method was successfully applied to determine ASP and OMP in tablet 
dosage form. The result obtained for ASP and OMP were comparable with corresponding 
labeled amounts. The results were tabulated in table 4. 
Conclusions 
The proposed method has advantage of simplicity and convenience for the separation and 
quantitation of ASP and OMP  in the combination which can be used for the assay of their 
dosage form. Also, the low solvent consumption and short analytical run time lead to 
environmentally friendly chromatographicprocedure. The method is accurate, precise,rapid and 
selective for simultaneous estimation of Aspirin and Omeprazole in tablet dosage form. Hence 
itcan be conveniently adopted for routine analysis. 
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